Literature DB >> 28854086

Myeloproliferative Neoplasms.

Jerry L Spivak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28854086     DOI： 10.1056/NEJMc1708485

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  Treatments targeting MDS genetics: a fool's errand?

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders.

Authors:  David A Williams
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

3.  Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.

Authors:  Korsuk Sirinukunwattana; Alan Aberdeen; Helen Theissen; Nikolaos Sousos; Bethan Psaila; Adam J Mead; Gareth D H Turner; Gabrielle Rees; Jens Rittscher; Daniel Royston
Journal:  Blood Adv       Date:  2020-07-28

Review 4.  Immunotherapy in Myeloproliferative Diseases.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

Review 5.  Dysregulated iron metabolism in polycythemia vera: etiology and consequences.

Authors:  Yelena Z Ginzburg; Maria Feola; Eran Zimran; Judit Varkonyi; Tomas Ganz; Ronald Hoffman
Journal:  Leukemia       Date:  2018-07-24       Impact factor: 11.528

6.  Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Authors:  Marte Karen Brattås; Kyrre Lilleeng; Randi Hovland; Ingvild Jenssen Lægreid; Marta Vorland; Friedemann Leh; Øystein Bruserud; Bjørn Tore Gjertsen; Håkon Reikvam
Journal:  Biomark Res       Date:  2018-11-21

7.  Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.

Authors:  Richard T Silver; Spencer Krichevsky
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

Review 8.  DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters?

Authors:  Raquel Ordoñez; Nicolás Martínez-Calle; Xabier Agirre; Felipe Prosper
Journal:  Cancers (Basel)       Date:  2019-09-24       Impact factor: 6.639

9.  68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms.

Authors:  Sabrina Kraus; Alexander Dierks; Leo Rasche; Olivia Kertels; Malte Kircher; Andreas Schirbel; Josip Zovko; Torsten Steinbrunn; Raoul Tibes; Hans-Jürgen Wester; Andreas K Buck; Hermann Einsele; K Martin Kortüm; Andreas Rosenwald; Constantin Lapa
Journal:  J Nucl Med       Date:  2021-05-28       Impact factor: 11.082

10.  Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden.

Authors:  Theodoros Karantanos; Shruti Chaturvedi; Evan M Braunstein; Jerry Spivak; Linda Resar; Styliani Karanika; Donna M Williams; Ophelia Rogers; Christopher D Gocke; Alison R Moliterno
Journal:  Blood Adv       Date:  2020-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.